A US-based company is set to provide a gene therapy that increases production of the anti-ageing protein klotho, aiming to extend longevity. This therapy will be administered at clinics outside the United States, thereby avoiding FDA regulatory approval.
The approach has sparked ethical and regulatory concerns regarding the safety and effectiveness of offering unapproved treatments overseas. Critics worry about the lack of rigorous oversight and potential health risks for patients receiving this therapy.
